First Solar heads into the final weeks before its July 28 earnings with a sharply split picture — the analyst community turning more constructive even as insiders trim at the highs and short sellers edge back in.
The Street's upgraded view is the most concrete signal this week. Mizuho raised its target to $300 from $243 on June 15, keeping an Outperform rating, while UBS pushed its Buy target to $330 from $290 on June 11 — both moves coming after the stock's 13% gain over the past month to around $264. The lone dissenter arrived this week when Bernstein initiated coverage with an Underperform and a $217 target, sitting well below the current price and the analyst consensus mean near $246. That consensus figure is actually below where FSLR trades right now, which makes the UBS and Mizuho upgrades more influential to the narrative than the raw average implies — a handful of bulls have moved decisively above the pack. Earlier in April, Barclays and Citigroup had both trimmed targets on tariff concerns, framing the recent wave of upgrades as a sentiment reversal rather than routine housekeeping.
The bull case rests on First Solar's position as the dominant US thin-film manufacturer: domestic content advantages, a growing utility-scale order book, and improving cadmium telluride pricing that some analysts project could lift 2026 revenues toward $6.3 billion with gross margins climbing to around 20%. The bear case is harder to dismiss at current levels. Bernstein's entry at Underperform echoes a concern that roughly a third of investors hold — that ongoing module quality and underperformance issues could force a guidance cut, and that rising global supply is quietly compressing average selling prices. The EV/EBITDA sits near 9x, which looks modest in isolation, but the forward earnings picture is deteriorating: the factor score for 12-month forward EPS year-on-year change ranks in the bottom quartile of the universe. Value looks attractive; growth trajectory does not.
Insider selling is the other wrinkle. CEO Mark Widmar sold shares across multiple tranches on May 26, totaling roughly $1.4 million at prices in the mid-$260s to low-$270s. An HR director followed with a $2.9 million sale on May 28, and a senior officer sold a further $906,000 on June 2. Collectively, insider net selling over the past 90 days comes to roughly $6.8 million. None of these transactions carried high significance scores — the trades appear to be routine plan sales rather than a directional signal — but the timing at a 30-day high does add a note of caution for investors trying to read inside sentiment.
Short positioning has pulled back from a recent peak but remains meaningful at 8% of free float. From a high around 9.2 million shares shorted in early June, the position has trimmed by roughly 500,000 shares. The lending market gives shorts no particular edge here: availability is exceptionally loose at 1,397%, meaning there are roughly fourteen shares available to borrow for every one already lent out. Cost to borrow is running well below 0.5%, easing about 17% over the past week. Nothing in the lending data points toward a squeeze. Options positioning leans mildly bullish — the put/call ratio is running slightly below its 20-day average at 0.56, near its lowest level of the past year, suggesting call demand is outpacing put buying even after Tuesday's 3.3% pullback.
The next concrete test is the July 28 Q1 earnings print. The prior quarter delivered a modest 1.6% next-day gain; the print before that — in late April — drove an 11% rally with a further 12.6% over the following week, a reaction that appears to have anchored much of the recent bullishness. Whether the Street's freshly lifted targets prove prescient or Bernstein's Underperform proves early will depend heavily on what management says about module quality, backlog coverage, and whether the pricing environment through 2027 is firming or deteriorating.
See the live data behind this article on ORTEX.
Open FSLR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
